Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
arterolane + piperaquine + mefloquine
- Development stage
- Unknown
- Lead developer
- Sun Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A triple antimalarial combination therapy that combines arterolane (a synthetic ozonide antimalarial), piperaquine (a long-acting bisquinoline), and mefloquine. This combination was developed to reduce the risk of antimalarial resistance by combining a potent, rapidly cleared synthetic ozonide with two more slowly eliminated partner drugs. Clinical trials have shown it to be highly efficacious and safe for the treatment of uncomplicated falciparum malaria in children.
02
Targets
CALR (Calreticulin)Hemeβ-HematinPfHRP2 (Plasmodium falciparum histidine-rich protein II)PfMDR1 (Plasmodium falciparum multidrug resistance protein 1)
Beyond the preview
Go deeper on arterolane + piperaquine + mefloquine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on arterolane + piperaquine + mefloquine.